{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oligoastrocytoma%2C+Mixed&page=2", "query": { "condition": "Oligoastrocytoma, Mixed", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oligoastrocytoma%2C+Mixed&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-21T23:34:24.976Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00303849", "title": "Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anaplastic Oligoastrocytoma", "Anaplastic Oligodendroglioma", "Mixed Glioma", "Oligoastrocytoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Etoposide Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mannitol", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Sodium Thiosulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 33, "start_date": "2005-09-15", "completion_date": "2021-03-12", "has_results": false, "last_update_posted_date": "2022-03-17", "last_synced_at": "2026-05-21T23:34:24.976Z", "location_count": 2, "location_summary": "Minneapolis, Minnesota • Portland, Oregon", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00303849" }, { "nct_id": "NCT00049127", "title": "Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Anaplastic Oligodendroglioma", "Adult Mixed Glioma", "Adult Oligodendroglioma", "Recurrent Adult Brain Neoplasm" ], "interventions": [ { "name": "Imatinib Mesylate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2003-06", "completion_date": "2019-09-01", "has_results": true, "last_update_posted_date": "2019-10-21", "last_synced_at": "2026-05-21T23:34:24.976Z", "location_count": 229, "location_summary": "Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 137 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Aurora", "state": "Illinois" }, { "city": "Bloomington", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00049127" }, { "nct_id": "NCT00024557", "title": "Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Glioma", "Glioblastoma Multiforme", "Anaplastic Astrocytoma", "Mixed Oligoastrocytoma", "Malignant Astrocytoma" ], "interventions": [ { "name": "IL13-PE38QQR", "type": "DRUG" }, { "name": "targeted fusion protein therapy", "type": "PROCEDURE" }, { "name": "surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "INSYS Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2001-06", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2011-06-06", "last_synced_at": "2026-05-21T23:34:24.976Z", "location_count": 4, "location_summary": "San Francisco, California • New Haven, Connecticut • New York, New York + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00024557" }, { "nct_id": "NCT02423525", "title": "Safety Study of Afatinib for Brain Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Cancer" ], "interventions": [ { "name": "Afatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Santosh Kesari", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2016-12", "completion_date": "2021-08", "has_results": false, "last_update_posted_date": "2022-03-10", "last_synced_at": "2026-05-21T23:34:24.976Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02423525" }, { "nct_id": "NCT01250470", "title": "Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Astrocytoma", "Anaplastic Oligoastrocytoma", "Anaplastic Oligodendroglioma", "Giant Cell Glioblastoma", "Glioblastoma", "Gliosarcoma", "Mixed Glioma", "Recurrent Brain Neoplasm" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Montanide ISA-51/Survivin Peptide Vaccine", "type": "DRUG" }, { "name": "Sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2012-09-05", "completion_date": "2014-05-29", "has_results": false, "last_update_posted_date": "2017-02-27", "last_synced_at": "2026-05-21T23:34:24.976Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01250470" }, { "nct_id": "NCT00024570", "title": "Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Glioma", "Glioblastoma Multiforme", "Anaplastic Astrocytoma", "Mixed Oligoastrocytoma" ], "interventions": [ { "name": "IL13-PE38QQR", "type": "DRUG" }, { "name": "targeted fusion protein therapy", "type": "PROCEDURE" }, { "name": "surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "INSYS Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2000-11", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2014-11-14", "last_synced_at": "2026-05-21T23:34:24.976Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00024570" }, { "nct_id": "NCT00004259", "title": "Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "BCNU 80mg/m2", "type": "DRUG" }, { "name": "TMZ 200mg/m2", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "CCNU", "type": "DRUG" }, { "name": "BCNU 150mg/m2", "type": "DRUG" }, { "name": "BCNU 200mg/m2", "type": "DRUG" }, { "name": "TMZ 150mg/m2 six 6-week cycles", "type": "DRUG" }, { "name": "TMZ 150mg/m2 six 8-week cycles", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 230, "start_date": "2000-06", "completion_date": "2018-05-14", "has_results": true, "last_update_posted_date": "2019-09-12", "last_synced_at": "2026-05-21T23:34:24.976Z", "location_count": 92, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Chico, California + 71 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Chico", "state": "California" }, { "city": "Fairfield", "state": "California" }, { "city": "Vacaville", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004259" }, { "nct_id": "NCT01966809", "title": "Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Tumor, Recurrent" ], "interventions": [ { "name": "Photofrin photodynamic therapy.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Harry T Whelan, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2015-06", "completion_date": "2017-12-19", "has_results": true, "last_update_posted_date": "2019-08-20", "last_synced_at": "2026-05-21T23:34:24.976Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01966809" }, { "nct_id": "NCT00445965", "title": "Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Intraocular Melanoma", "Lung Cancer", "Melanoma (Skin)", "Metastatic Cancer", "Neuroblastoma", "Ovarian Cancer", "Retinoblastoma", "Sarcoma", "Small Intestine Cancer" ], "interventions": [ { "name": "DNA analysis", "type": "GENETIC" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "iodine I 131 monoclonal antibody 3F8", "type": "RADIATION" }, { "name": "131I-3F8", "type": "RADIATION" } ], "intervention_types": [ "GENETIC", "OTHER", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 78, "start_date": "2006-01", "completion_date": "2023-02-01", "has_results": true, "last_update_posted_date": "2024-04-04", "last_synced_at": "2026-05-21T23:34:24.976Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00445965" }, { "nct_id": "NCT00362570", "title": "Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oligoastrocytoma, Mixed", "Anaplastic Oligodendroglioma" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2005-05", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2017-11-30", "last_synced_at": "2026-05-21T23:34:24.976Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00362570" } ] }